{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:16:29Z","timestamp":1788498989330,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Ischemic stroke is a leading cause of death and long-term disability, and traditional Chinese medicine (TCM) is widely used alongside conventional care in East Asia. We reviewed randomized controlled trials (RCTs) of adjunctive TCM in ischemic stroke, analyzing the evidence by clinical phase and by individual formulation rather than as a single treatment class. We searched seven bibliographic databases and one clinical trial registry to 8 April 2026, for trials of adults with imaging-confirmed ischemic stroke given a TCM formulation in addition to standard care, compared with placebo plus standard care or standard care alone. Nine RCTs enrolling 12,348 randomized participants were eligible. They evaluated eight formulations across three clinical phases, with different outcome instruments and follow-up of 14 days to 24 months, so we did not pool them; each trial is reported with its published effect measure and synthesized under Synthesis Without Meta-analysis guidance. In acute treatment, Tongxinluo improved a favorable functional outcome at 90 days (modified Rankin Scale [mRS] 0 to 1: 640\/973 vs. 575\/973; odds ratio [OR] 1.33, 95% confidence interval [CI] 1.11 to 1.60), and Panax notoginseng saponins improved functional independence at 3 months (mRS 0 to 2: 1,328\/1,487 vs. 1,218\/1,479; OR 1.95, 95% CI 1.56 to 2.44); these thresholds are related but not interchangeable. Angong Niuhuang Pills and NeuroAiD (MLC601) showed no clear difference, and a small trial of Xueshuan Xinmai tablets reported no between-group estimate. In early recovery, Qizhitongluo improved lower-limb motor function at 12 weeks (mean difference 1.81 points, 95% CI 0.88 to 2.74). In secondary prevention, Naoxintong reduced 2-year recurrence [hazard ratio (HR) 0.665, 95% CI 0.492 to 0.899] and Dengzhan Shengmai reduced 1-year stroke incidence (HR 0.70, 95% CI 0.50 to 0.98). GRADE certainty, rated separately by formulation, clinical phase, and outcome, ranged from moderate to very low. Safety reporting was incomplete, so comparative safety cannot be established. The review was not prospectively registered and no dated protocol preceded screening. The findings are formulation-specific, unreplicated, and do not support routine clinical use or any conclusion about TCM as a treatment class.<\/jats:p>","DOI":"10.3389\/fmed.2026.1884399","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:27:22Z","timestamp":1788496042000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjunctive traditional Chinese medicine for ischemic stroke: a systematic review with structured narrative synthesis and GRADE assessment of randomized controlled trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Ting","family":"Liu","sequence":"first","affiliation":[{"name":"Medical College","place":["Qilu Institute of Technology, Jinan, China"]},{"name":"Department of Traditional Chinese Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan","place":["Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjing","family":"Lu","sequence":"additional","affiliation":[{"name":"Medical College","place":["Qilu Institute of Technology, Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical College","place":["Qilu Institute of Technology, Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Ding","sequence":"additional","affiliation":[{"name":"Medical College","place":["Qilu Institute of Technology, Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqian","family":"Kong","sequence":"additional","affiliation":[{"name":"Medical College","place":["Qilu Institute of Technology, Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","article-title":"Global burden of stroke: insights and trends from GBD 2021","author":"Luu","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association\/American stroke association","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke."},{"key":"B3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12883-025-04361-8","article-title":"Study on delay factors and time to hospital arrival after acute stroke in patients at Shahid Rajaei hospital, Tonekabon (2022-2023)","volume":"25","author":"Farokhfar","year":"2025","journal-title":"BMC Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1402729","DOI":"10.3389\/fneur.2024.1402729","article-title":"Stroke rehabilitation: from diagnosis to therapy","volume":"15","author":"Li","year":"2024","journal-title":"Front Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1561688","DOI":"10.3389\/fphar.2025.1561688","article-title":"Traditional, complementary, and integrative medicine in the management of ischemic stroke: a narrative review","volume":"16","author":"Sowmiya","year":"2025","journal-title":"Front Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e8830","DOI":"10.1097\/MD.0000000000008830","article-title":"Therapeutic effect of Chinese herbal medicines for post stroke recovery: a traditional and network meta-analysis","volume":"96","author":"Han","year":"2017","journal-title":"Medicine (Baltimore)."},{"key":"B7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms23010014","article-title":"Neuroinflammation in cerebral ischemia and ischemia\/reperfusion injuries: from pathophysiology to therapeutic strategies","volume":"23","author":"Jurcau","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e2433463","DOI":"10.1001\/jamanetworkopen.2024.33463","article-title":"Tongxinluo and functional outcomes among patients with acute ischemic stroke: a randomized clinical trial","volume":"7","author":"Dong","year":"2024","journal-title":"JAMA Netw Open."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e2317574","DOI":"10.1001\/jamanetworkopen.2023.17574","article-title":"Efficacy and safety of Panax notoginseng saponins in the treatment of adults with ischemic stroke in china: a randomized clinical trial","volume":"6","author":"Wu","year":"2023","journal-title":"JAMA Netw Open."},{"key":"B10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13020-025-01101-5","article-title":"Effect of age on the efficacy and safety of Panax notoginseng saponins in acute ischemic stroke: a prespecified secondary analysis of the PANDA study","volume":"20","author":"Li","year":"2025","journal-title":"Chin Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s11655-022-3586-8","article-title":"Naoxintong capsule for secondary prevention of ischemic stroke: a multicenter, randomized, and placebo-controlled trial","volume":"28","author":"Yu","year":"2022","journal-title":"Chin J Integr Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ctim.2019.08.015","article-title":"The add-on effect of dengzhan shengmai capsules on secondary prevention of ischemic stroke: a multicentre, randomised, placebo-controlled clinical trial","volume":"46","author":"Cai","year":"2019","journal-title":"Complement Ther Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"105464","DOI":"10.1016\/j.phrs.2021.105464","article-title":"Effect of Qizhitongluo capsule on lower limb rehabilitation after stroke: a randomized clinical trial","volume":"165","author":"Yu","year":"2021","journal-title":"Pharmacol Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1161\/STROKEAHA.113.002055","article-title":"Chinese medicine neuroaid efficacy on stroke recovery: a double-blind, placebo-controlled, randomized study","volume":"44","author":"Chen","year":"2013","journal-title":"Stroke."},{"key":"B15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1159\/000247001","article-title":"A double-blind, placebo-controlled, randomized phase II pilot study to investigate the potential efficacy of the traditional Chinese medicine Neuroaid (MLC 601) in enhancing recovery after stroke (TIERS)","volume":"28","author":"Kong","year":"2009","journal-title":"Cerebrovasc Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1047650","DOI":"10.3389\/fphar.2023.1047650","article-title":"Methodological, reporting, and evidence quality of systematic reviews of traditional Chinese medicine for ischemic stroke","volume":"14","author":"Sun","year":"2023","journal-title":"Front Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ."},{"key":"B18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"3367650","author":"Guyatt","year":"2008","journal-title":"BMJ."},{"key":"B19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"B20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"B22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0254-6272(13)60034-5","article-title":"Randomized, double-blind, parallel-controlled clinical trial on correspondence of prescriptions and traditional Chinese medicine syndrome of ischemic stroke","volume":"32","author":"Gao","year":"2012","journal-title":"J Tradit Chin Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/CM9.0000000000003133","article-title":"Safety and efficacy of Angong Niuhuang pills in patients with moderate-to-severe acute ischemic stroke (ANGONG TRIAL): a randomized double-blind placebo-controlled pilot clinical trial","volume":"138","author":"Li","year":"2025","journal-title":"Chin Med J (Engl)."},{"key":"B24","doi-asserted-by":"publisher","first-page":"15244","DOI":"10.1038\/s41598-017-15456-9","article-title":"The positive effects of Xueshuan Xinmai tablets on brain functional connectivity in acute ischemic stroke: a placebo controlled randomized trial","volume":"7","author":"Wei","year":"2017","journal-title":"Sci Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.19852\/j.cnki.jtcm.20230526.002","article-title":"Effectiveness and safety of Angong Niuhuang pill in treatment of acute stroke: a systematic review and meta-analysis","volume":"43","author":"Meng","year":"2023","journal-title":"J Tradit Chin Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jep.2019.03.043","article-title":"Angong Niuhuang Pill as adjuvant therapy for treating acute cerebral infarction and intracerebral hemorrhage: a meta-analysis of randomized controlled trials","volume":"237","author":"Liu","year":"2019","journal-title":"J Ethnopharmacol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1884399\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:27:24Z","timestamp":1788496044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1884399\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":26,"alternative-id":["10.3389\/fmed.2026.1884399"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1884399","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1884399"}}